Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should ...

But does it cost too much?

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.